HORSHAM, Pa.--(BUSINESS WIRE)--PhotoMedex, Inc. (NASDAQ and TASE:PHMD) today announced financial results for the fourth quarter and full year ended December 31, 2013. Financial highlights include:
Fourth Quarter 2013 (all comparisons are with the fourth quarter of 2012):
- Revenues of $63.5 million, an increase of 16%
- Gross profit of $50.8 million, an increase of 18%
- Net income of $3.2 million, compared with net income of $5.9 million
- Earnings per diluted share of $0.16, compared with earnings per diluted share of $0.27
- Adjusted earnings per diluted share, excluding certain items of $0.28
- Consumer revenues of $53.6 million, an increase of 16%
- Global Direct-to-consumer channel revenues of $39.4 million, an increase of 31%
- Global retail and home shopping channel revenues of $13.6 million, an increase of 10%
- Global Distributor consumer channel revenues of $0.6 million, a decrease of 84%
- XTRAC® psoriasis and vitiligo treatment recurring revenues of $4.7 million, an increase of 80%
- Cash generated from operations of $13.9 million
- Repurchase of $12.0 million or 972,770 shares common stock at an average price of $12.35 per share
- Cash, cash equivalents and short-term investments as of December 31, 2013 of $59.5 million, or $3.04 per diluted share
Full Year 2013 (all comparisons are with the full year 2012):
- Revenues of $224.7 million, an increase of 2% with revenues from all channels; excluding Japan’s consumer revenue in both years, revenues increased 6%
- Gross profit of $179.6 million, an increase of 3%
- Net income of $18.4 million, compared with net income of $22.5 million
- XTRAC franchise installed base of 501 sites compared with 361 sites, an increase of 39%
- Earnings per diluted share of $0.89, compared with earnings per diluted share of $1.08
- Adjusted earnings per diluted share, excluding certain items of $1.01
- Consumer revenues excluding Japan of $177.3 million, compared with $169.1 million, represents an increase of 5%
- Optimization of tax planning and management of cash balances between intercompany international subsidiaries via a $10 million line of credit in December 2013, which was repaid after year end
As announced on February 13, 2014, PhotoMedex signed a definitive agreement to acquire all outstanding shares of LCA-Vision Inc. for $5.37 per share in cash, or approximately $106 million. Subject to certain conditions including approval by LCA-Vision shareholders, the transaction is expected to close in the second quarter of 2014. The transaction is expected to be accretive to PhotoMedex’s cash EPS in 2014, excluding transaction-related items.
Dr. Dolev Rafaeli, PhotoMedex CEO, commented, “We are reporting record revenues for both the quarter and the year, and we achieved these results without any consumer sales from Japan in the second half of the year. Our North American Media Efficiency Ratio was outstanding during the fourth quarter, with MERs as high as 3.86 during certain weeks. In addition, we were successful in cross-selling Neova products to our direct-to-consumer customers, with consumer sales from this skin care product line up 21% over the third quarter of 2013. Our direct-to-consumer revenues were up 34% on a sequential quarter basis and were up 31% over the prior year. Recently, a clinical study by Emanuele, et al. published in the March 2014 edition of Journal of Drugs in Dermatology about indications for prevention of sun damage associated with skin aging and non-melanoma skin cancer reported that Neova DNA Total Repair and DNA Damage Control ACTIVE SPF 44 were shown to be the most efficient repair and protect product combination among the commercially available products compared. Also, we initiated pre-launch activities for our Kyrobak® product for the treatment of lower back pain, with initial media testing that resulted in positive indications that will be further expanded in the first quarter of 2014.”
Dr. Rafaeli continued, “We have made excellent progress in broadening awareness of XTRAC for the treatment of psoriasis and vitiligo as demonstrated by the 12% sequential increase in treatment revenues and the 80% increase year-over-year. XTRAC is a source of recurring revenues to the treating physician and to PhotoMedex once a patient has been acquired. As a recent endorsement for the efficacy of XTRAC, a clinical study published recently in the Journal of Dermatological Treatment by Dr. John Y. M. Koo, M.D. of the Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco and a member of our scientific advisory board and others shows that the XTRAC Velocity excimer laser when used in combination with a topical therapy is as effective as biologics, but without the systemic immune suppression or other potentially harmful side effects for the treatment of moderate to severe psoriasis. We are optimistic for continued rapid growth in the physician recurring revenue side of our business, and look forward to gaining revenue from XTRAC treatments and Neova product sales from the underutilized LasikPlus infrastructure and professional staff, upon completion of our acquisition of LCA-Vision.”
“International expansion is a significant component of our growth strategy for our no!no! brand,” he added. “In the fourth quarter we initiated media testing in Brazil with encouraging results. In addition, we continue to build our brand awareness in Germany and Great Britain and are confident we have the pieces in place for a very successful year ahead with each major business segment making significant contributions to our growth in 2014.”
Reported Financial Results
Revenues for the fourth quarter of 2013 were $63.5 million, an increase of 16% over revenues for the fourth quarter of 2012 of $54.8 million.
Gross profit for the fourth quarter of 2013 was $50.8 million, or 80.0% of sales, compared with gross profit of $43.0 million, or 78.5% of sales, in the prior year’s fourth quarter, an increase of 150 basis points.
Net income for the fourth quarter of 2013 was $3.2 million or $0.16 per diluted share, which included $1.2 million in stock-based compensation expense and $1.6 million in depreciation and amortization expenses. This compares with net income for the fourth quarter of 2012 of $5.9 million or $0.27 per diluted share, which included $1.4 million in stock-based compensation expense and $1.4 million in depreciation and amortization expenses.
Revenues for the year ended December 31, 2013 were $224.7 million, an increase of 2% over revenues for the year ended December 31, 2012 of $220.7 million.
Gross profit for 2013 was $179.6 million, or 80.0% of sales, compared with $174.0 million, or 78.9% of sales, for 2012, an increase of 110 basis points. Net income for 2013 was $18.4 million or $0.89 per diluted share, which included $5.0 million in stock-based compensation expense and $6.1 million in depreciation and amortization expenses. This compares with net income for 2012 of $22.5 million or $1.08 per diluted share, which included $6.2 million in stock-based compensation expense and $5.6 million in depreciation and amortization expenses.
As of December 31, 2013, the Company had cash, cash equivalents and short-term investments of $59.5 million. During the 2013 fourth quarter the Company repurchased 972,770 shares of its common stock in the open market at an average price of $12.35 per share, for a total of $12.0 million.
In December 2013 the Company entered into a $15.0 million line of credit with JP Morgan Chase to facilitate repayment of temporary advances from its non-U.S. subsidiaries to comply with certain IRS regulations. The Company took an advance of $10 million against this line at December 31, 2013. The advance was repaid in full after year end.
Non-GAAP Financial Measures
To supplement PhotoMedex’s consolidated financial statements presented in accordance with GAAP, PhotoMedex provides certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP adjusted income and non-GAAP adjusted income per share.
PhotoMedex’s reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP measures. These non-GAAP measures are provided to enhance investors' overall understanding of PhotoMedex’s current financial performance and to provide further information for comparative purposes.
Specifically, the Company believes the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains and losses that may not be indicative of the Company’s core operating results and business outlook. In addition, PhotoMedex believes non-GAAP measures enhance the comparability of results against prior periods. Reconciliation to the most directly comparable GAAP measure of all non-GAAP measures included in this press release is as follows:
Three Months Ended Dec. 31,
|For the Year Ended Dec. 31|
(ooo's) except per share amounts
|Net income as reported||$||3,185||$||5,894||$||18,377||$||22,489|
Depreciation and amortization expense
Interest expense, net
Income tax expense
Stock-based compensation expense
|Non-GAAP adjusted income||$||7,282||$||9,538||$||33,861||$||39,133|
Fully diluted shares outstanding at December 31
Non-GAAP adjusted income per share
Excluding certain litigation expenses of $0.8 million, advertising expenses of $1.4 million for product sales not shipped until 2014, expenses associated with the relocation of corporate headquarters of $0.4 million and inventory valuation allowances of $0.6 million, earnings per diluted share were approximately $0.28 for the fourth quarter and $1.01 for the full year.
PhotoMedex will hold an investor conference call to discuss the Company’s 2013 fourth quarter and full year financial results and to answer questions today, March 13, 2014 beginning at 11:00 a.m. EST (5:00 p.m. Israel time).
To participate in the conference call, dial toll free 877-397-0292 or International/toll 719-325-4750 (and confirmation code # 3316100). For the convenience of our Israeli participants, a local/toll free number (1-80-925-8243) has been set up (the confirmation code remains the same # 3316100). If you are unable to participate in the live call, a digital replay will be available from Thursday, March 13, 2014 from 2:00 p.m. ET to Thursday, March 27, 2014 at 2:00 p.m. ET, by dialing toll free 888-203-1112 or International/toll 719-457-0820 (Israeli participants may dial 1-80-924-6038) and using confirmation code # 3316100.
The live webcast of the conference call will be available online by going to www.photomedex.com and clicking on the link to Investor Relations, and at www.streetevents.com. The online replay will be available shortly after the call has been completed.
A separate Form 10-K, including 2013 consolidated financial statements, will be filed with the Securities and Exchange Commission on or by March 17, 2014.
PhotoMedex is a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer) and photo damage. Its experience in the physician market provides the platform to expand its skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. As a result of its December 2011 merger with Radiancy Inc., PhotoMedex has added a range of home-use devices under the no!no!™ brand, for various indications including hair removal, acne treatment and skin rejuvenation. The company also offers a professional product line for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements, including, but not limited to, statements relating to PhotoMedex’s future financial performance, strategies, potential sales and earnings growth, and some portions of the conference call, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans will also contain “forward-looking statements”, each within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements regarding product development, product extensions, product integration or product marketing; any statements regarding continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, there are risks and uncertainties related to successfully integrating the products and employees of the Company and Radiancy, as well as the ability to ensure continued regulatory compliance, performance and/or market growth. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described from time-to-time under the caption “Risk Factors” and elsewhere in the Company’s SEC filings and reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to, implied or expressed in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company, inherently involve significant risks and uncertainties and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments will cause its views to change. The information contained in this conference call speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
-- Financial Statements follow --
CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended
(ooo's) except per share amounts
|Cost of revenues||12,713||11,772||45,035||46,642|
|Selling and marketing||36,761||31,299||127,528||116,487|
|General and administrative||8,851||4,737||26,750||27,330|
|Research and development and engineering||914||768||3,306||2,914|
|Interest and other financing income (expense), net||232||511||702||(351||)|
|Income before taxes expense||4,483||6,726||22,747||26,927|
|Income tax expense (benefit)||1,298||832||4,370||4,438|
|Net income per share:|
|Shares used in computing net income per share:|
|1 Includes: depreciation and amortization||1,609||1,435||6,119||5,611|
|Share-based compensation expense||1,190||1,380||4,985||6,197|
|Three Months ended Dec. 31,||Year ended Dec 31,|
Retailer and home shopping channels
|Dec. 31, 2013||Dec. 31, 2012|
|Cash, cash equivalents and short-term investments||$||59,501||$||62,348|
|Accounts receivable, net||27,218||19,064|
|Other current assets||25,638||32,294|
|Property and equipment, net||10,489||6,759|
|Other non-current assets||70,536||68,958|
|Liabilities and Stockholders' Equity|
|Accounts payable and accrued liabilities||$||40,047||$||34,618|
|Other current liabilities||5,961||5,259|
|Bank and lease notes payable||10,920||619|
|Total Liabilities and Stockholders' Equity||$||220,929||$||211,890|
For the Three Months ended
For the Year Ended
|CASH FLOWS FROM OPERATING ACTIVITIES:|
|Adjustments to reconcile net income to net cash provided by operating activities:|
|Depreciation and amortization||1,609||1,435||6,119||5,611|
|Provision for doubtful accounts||2,530||1,225||5,958||4,629|
|Deferred income taxes||(849||)||(2,800||)||2,589||(2,330||)|
|Changes in assets and liabilities:|
|(Increase) decrease in:|
|Net cash provided by operating activities||13,866||14,034||25,270||25,065|
|CASH FLOWS FROM INVESTING ACTIVITIES:|
|Lasers placed in service||(1,046||)||(1,092||)||(5,476||)||(3,221||)|
|Purchases of PP&E, net||(233||)||(296||)||(943||)||(573||)|
|Net cash provided by (used in) investing activities||3,044||(1,423||)||(2,681||)||(21,863||)|
|CASH FLOWS FROM FINANCING ACTIVITIES:|
|Proceeds from exercise of options/issuance (share-purchase) of securities, net||(12,047||)||(5,401||)||(31,006||)||27,057|
|Proceeds from issuance of debt||10,000||-||10,000||-|
|Repayments of debt||(14||)||(8||)||(666||)||(2,465||)|
|Net cash (used in) provided by financing activities||(2,061||)||(5,409||)||(21,672||)||24,592|
|EFFECT OF EXCHANGE RATE CHANGES ON CASH||69||339||123||5|
|NET INCREASE IN CASH AND CASH EQUIVALENTS||14,918||7,541||1,040||27,799|
|CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD||30,470||36,807||44,348||16,549|
|CASH AND CASH EQUIVALENTS, END OF PERIOD||$||45,388||$||44,348||$||45,388||$||44,348|